阿托伐他汀联合别嘌醇对高脂血症合并高尿酸血症患者血脂血尿酸的影响

Influence of atorvastatin combined with allopurinol on blood lipid, blood uric acid of patients with hyperlipemia combined with hyperuricemia

目的探讨阿托伐他汀联合别嘌醇对高脂血症合并高尿酸血症患者血脂和血尿酸的影响。方法将102例高脂血症合并高尿酸血症患者随机均分为A、B、C三组，每组34例。A组患者给予阿托伐他汀钙片与别嘌醇片，B组患者给予阿托伐他汀钙片，C组患者给予别嘌醇片，各组疗程均为4周。观察各组患者治疗前后甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）、尿酸（UA）、丙氨酸转氨酶（ALT）、肌酸磷酸激酶（CK）、尿素氮（BUN）水平及不良反应。结果治疗后，各组患者TG、TC、LDL水平均显著低于同组治疗前，且A、B组低于C组；各组患者UA水平均显著低于同组治疗前，且A、B组低于C组，A组低于B组；A、B组患者ALT水平、各组患者CK水平和A、C组患者BUN水平均高于同组治疗前，且A、B组CK水平高于C组，A组高于B组，差异有统计学意义（P〈0．05）；BUN水平B组患者治疗前后及各组间比较差异无统计学意义（P〉0．05）。治疗期间，A组有1例（2．94％）患者出现胃肠道反应，无痛风发作；B组有3例（8．82％）患者出现胃肠道反应，无痛风发作；C组有4例患者出现胃肠道反应，2例出现痛风发作，不良反应率为17．65％。结论阿托伐他汀联合别嘌醇可显著降低高脂血症合并高尿酸血症患者血脂、UA水平，且安全性较好。

Objective To investigate the influence of atorvastatin combined with allopurinol on blood lipid, blood uric acid （BUA） of patients with hyperlipemia combined with hyperuricemia. Methods 102 cases of hyperlipemia combined with hyperuricemia were selected and divided into group A, B, C, 34 cases in each group. Group A was given atorvastatin combined with allopurinol, group B was given atorvastatin, and group C was given allopurinol, the course of the treatment was 4 weeks. Observed the levels ofTG, TC, LDL, HDL, UA, ALT, CK, BUN, and adverse reactions of the patients. Results After treatment, the levels of TG, TC, LDL were all lower than those before treatment among three groups, and those of group A, B were lower than those of group C （P〈0.05）; the level of UA was lower than that before treatment among three groups, and those of group A, B were lower than that of group C, that of group A was lower than that of group B （P〈0.05）; the levels of ALT of group A, B, the levels of CK of three groups, and the levels of BUN of group A, C were all higher than those before treatment, the levels of CK of group A, B were higher than that of group C, that of group A was higher than that of group B （P〈0.05）, there was no statistically significant difference in the level of BUN before and after treatment in group B or among three groups （P〉0.05）. During the treatment, there was 1 case of gastrointestinal reaction in group A, 3 cases of gastrointestinal reaction in group B, 4 cases of gastrointestinal reaction and 2 cases of gout attack in group C. Conclusion Atorvastafin combined with allopurinol can obviously lower blood lipid, UA of patients with hyperlipemia combined with hyperuricemia, with high safety.